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Although palliative chemotherapy has been shown to prolong survival and improve quality of life, the survival of
advanced gastric cancer (AGC) patients remains poor. With the advent of targeted therapy, many molecular
targeted agents have been evaluated in clinical studies. Trastuzumab, an anti-HER2 monoclonal antibody, has
shown activity against HER2-positive AGC and becomes the first targeted agent approved in AGC. Drugs that
target epidermal growth factor receptor, including monoclonal antibody and tyrosine kinase inhibitor, do not
bring survival benefit to patients with AGC. Additionally, vascular endothelial growth factor inhibitors are also under
investigation. Ramucirumab has shown promising result. Other targeted agents are in preclinical or early clinical
development, such as mammalian target of rapamycinm inhibitors and c-MET inhibitors.Introduction
Approximately one million people are diagnosed each
year with gastric cancer, making it the fourth most com-
mon cancer and the second leading cause of cancer re-
lated death worldwide with an estimated 800,000 deaths
caused by the disease [1]. The incidence of gastric can-
cer varies widely according to geographic region and is
particularly common in eastern Asia [2]. According to
the 2012 Chinese cancer registry annual report, gastric
cancer is the third most common cancer and the second
leading cause of cancer related death in China [3]. The
only treatment that offers a potential cure is complete
resection of the tumor. However, in most of countries,
the majority of patients are diagnosed at advanced stages
and have a poor prognosis. Though first-line chemother-
apy for advanced gastric cancer (AGC) prolongs overall
survival (OS) and improves quality of life compared
with best supportive care (BSC). The median survival
of advanced gastric cancer patients who received pallia-
tive chemotherapy is approximately 7 to 11 months
[4-8]. In 2010, trastuzumab (Herceptin, Roche, Basel,
Switzerland), a recombinant humanized monoclonal
antibody that targets human epidermal growth factor
receptor-2 (HER2), had already been confirmed to be* Correspondence: xurh@sysucc.org.cn
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reproduction in any medium, provided the oreffective when combined with chemotherapy in HER2-
positive AGC patients [9]. Trastuzumab is the first tar-
geted agent that gets the indication in AGC, but it is not
the only targeted agents which have tried their applica-
tions in AGC. The other therapeutic strategies include:
epidermal growth factor receptor (EGFR) inhibitors,
vascular endothelial growth factor (VEGF) inhibitors,
hepatocyte growth factor (HGF) and its receptor c-MET
pathway inhibitor, mammalian target of rapamycinm
(m-TOR) inhibitor et al. This review will focus on the
recent progress in targeted agents for the treatment of
AGC (Table 1).
EGFR-signaling pathway
EGFR exists on the cell surface and is part of the family
of TK receptor including HER2. EGFR overexpression
has been reported in approximately 30% to 50% of
gastric cancers and is associated with poor prognosis
[10-14].
Anti-HER2 monoclonal antibodys
HER2, a transmembrane tyrosine kinase (TK) receptor,
is the preferred heterodimerization partner of the other
HER family members (HER1 or EGFR, HER3 and
HER4). The HER2-HER3 heterodimer plays a critical
role in oncogenic transformation in HER2-driven tumors
[15,16]. In breast cancer, amplification and overexpres-
sion of the HER2 gene is associated with poor outcomes,
higher mortality, and higher recurrence as well astd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Available targeted agents in advanced gastric cancer





Trastuzumab First line Double
blind
OS Cisplatin + fluoropyrimidine + Trastuzumab vs. Placebo Finished Positive
PhaseIIINCT01774786 Pertuzumab First line Double
blind
OS Trastuzumab + cisplatin + fluoropyrimidine + Pertuzumab
vs. Placebo
Ongoing Unknown
Phase III/IIINCT01641939 T-DM1 Second line Open
label
OS T-DM1 vs. Taxane Ongoing Unknown
PhaseIII TYTAN/
NCT00486954
Lapatinib Second line Open
label
OS Lapatinib vs. Paclitaxel Finished Negative
PhaseIII LOGiC/
NCT00680901
Lapatinib First line Double
blind





Cetuximab First line Open
label
PFS Capecitabine and cisplatin + Cetuximab vs. Placebo Finished Negative
PhaseIIIREAL-3/
NCT01234324









Bevacizumab First line Double
blind
OS Capecitabine + cisplatin + Bevacizumab vs. Placebo Finished Negative
PhaseIII REGARD/
NCT00917384
Ramucirumab Second line Double
blind
OS and BSC + Ramucirumab vs. Placebo Finished Positive
PhaseIIIRAINBOW/
NCT01170663
Ramucirumab Second line Double
blind
OS Paclitaxel + Ramucirumab vs. Placebo Ongoing Unknown
PhaseIIINCT01246960 Ramucirumab First line Double
blind
PFS mFOLFOX6+ Ramucirumab vs. Placebo Ongoing Unknown
PhaseIIINCT00970138 Apatinib Third line Double
blind
PFS Placebo vs.Apatinib Finishes Positive
PhaseIIINCT01512745 Apatinib Third line Double
blind
PFS placebo vs. apatinib Ongoing Unknown
PhaseIIINCT01747551 Aflibercept First line Double
blind









DCR Tivantinib Finished Modest
efficacy
PhaseIIINCT01662869 Onartuzumab First line Double
blind











OS Everolimus vs. Placebo Finished Negative
Abbreviation: HER2 human epidermal growth factor receptor-2, OS overall survival, EGFR epidermal growth factor receptor, PFS progression free survival, VEGF vascular endothelial growth factor, BSC best supportive
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tween HER2 status and prognosis in gastric cancer
remains controversial. In a few studies a correlation
between HER2 amplification or overexpression and
favorable survival was shown [20,21]. In a retrospect-
ive analysis from four Chinese clinical centers, the
HER2 status of 726 gastric cancer patients with all
stages was detected. They found that HER2 was not a
prognostic factor for gastric cancer patients [22]. A
systematic analysis of data from the literature indi-
cated that there was a clear trend towards a potential
role for HER2 as a negative prognostic factor in gas-
tric cancer patients [23].
Trastuzumab
In the ToGA trial, the addition of trastuzumab to
chemotherapy significantly improved OS compared with
chemotherapy alone in patients with HER2-positive
AGC. The HER2 positive rate was 22.1% in this study.
The median OS was improved significantly in the trastu-
zumab arm compared with the control arm [13.5 vs.
11.1 months, P = 0.0048; hazard ratio (HR), 0.74; 95%
confidence interval (CI), 0.60 to 0.91]. In subgroup ana-
lysis, the patients with HER2 immunohistochemistry
(IHC) 2+/fluorescence in situ hybridization + or IHC 3+
had a longer OS compared with the chemotherapy-
alone arm (16 months vs. 11.8 months). Moreover, the
addition of trastuzumab to chemotherapy in the ToGA
trial was well-tolerated, with no differences in the inci-
dence of grade 3 or 4 adverse events (AEs) between the
two groups [9]. Based on the result of ToGA study,
trastuzumab with chemotherapy was recommended for
HER2 overexpressing AGC (category 1 for combination
with cisplatin and fluoropyrimidine; category 2B for
combination with other chemotherapy agents; not rec-
ommended for use with anthracyclines) in the national
comprehensive cancer network guidelines of gastric can-
cer version 2 2012.
Pertuzumab
Pertuzumab is a monoclonal antibody that prevents
dimerization of HER2 with other HER family receptors
[24]. Its efficacy in combination with trastuzumab in
HER2-positive metastatic breast cancer patients has
been demonstrated in phase III clinical trials [25,26].
At the 2013 American Society of clinical oncology
(ASCO) meeting, the result of an international phase III
study was reported. This was a double-blind, placebo-
controlled, randomized phase III study and it was
designed to evaluate efficacy and safety of pertuzumab +
trastuzumab + chemotherapy in patients with HER2-
positive metastatic gastric or gastroesophageal junction
(GEJ) cancer. In this study, HER2-positive metastatic
gastric cancer patients were randomized 1:1 to receivetrastuzumab + cisplatin + fluoropyrimidine + pertuzumab
vs. placebo . Primary endpoint was OS. The result of this
study is worth looking forward to [27].T-DM1
T-DM1 is an antibody-drug conjugate in which trastuzu-
mab is conjugated to a cytotoxic compound, emtansine
[28]. Upon binding of the trastuzumab moiety to HER2,
T-DM1 is internalized into the tumor cell, releasing
the DM1 moiety, which inhibits microtubules. A trial
(NCT01641939) is now ongoing to examine the efficacy
and safety of T-DM1 compared with standard taxane
therapy in patients with HER2-positive gastric cancer in
second line setting. In this study, patients will be ran-
domized to one of the three groups, 3.6 mg/kg T-DM1
every 3 weeks, 2.4 mg/kg T-DM1 every week, or stand-
ard taxane therapy (Taxol 80 mg/m2/wk or docetaxol
75 mg/m2 q3wk), for at least four cycles (12 weeks).
Planned endpoints include OS.
The results of these studies are eagerly awaited to
examine the efficacy of this approach in patients with
HER2-positive AGC.HER-2 TKI
Lapatinib, a reversible dual TKI that affects both HER2
and EGFR, has also been clinically shown to be active
against HER2-positive breast cancer as a monotherapy
and in combination with capecitabine [29]. The TYTAN
study compared lapatinib and paclitaxel with paclitaxel
alone in patients with HER2-positive metastatic gastric
cancer in a second line setting. The primary endpoint of
the study was OS. Though lapatinib showed efficacy in
HER2 IHC 3+ subgroups, this study did not show an
improvement in OS. These results indicated that the
definition of HER2-positive AGC was very important
for the development of new anti-HER2 agents [30].
At the 2013 ASCO meeting, lapatinib in combination
with capecitabine plus oxaliplatin in HER2-positive ad-
vanced or metastatic gastroesophageal adenocarcinoma,
the LOGiC trial was reported. Primary endpoint of im-
proving OS was not met. The median OS in the lapati-
nib group and the control group was 12.2 months and
10.5 months, respectively, P = 0.3492. Improved OS was
seen in Asian patients and patients under 60 years old.
Secondary efficacy endpoints of progression free survival
(PFS), response rate (RR) and duration of response were
improved with addition of lapatinib. No new safety sig-
nal was identified, but increased toxicity was seen with
the addition of lapatinib to capecitabine and oxaliplatin,
particularly diarrhea and skin toxicity [31]. Prior to this
study, there was no evidence to support the use of lapa-
tinib in HER2-positive AGC.
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Manageable and expected safety profiles with substantial
activities were reported in phase II studies of cetuximab
plus various first line chemotherapy regimens in patients
with AGC [32-35].
In a prospective multi-center biomarker-oriented phase
III trial using cetuximab with folfiri as first-line treatment
in AGC, patients received weekly cetuximab (400 mg/m2
on day 1, subsequently 250 mg/m2) plus irinotecan and a
24-hour continuous infusion of folinic acid and 5-fu on
days 1, 8, 15, 22, 29 and 36 of a 50-day cycle, until disease
progress (PD). In 48 assessable patients, the overall re-
sponse rate was 46% and disease control rate (DCR)
was 79%. Median PFS and OS were 9.0 months (95% CI
7.1-15.6) and 16.5 months (95% CI 11.7-30.1), respectively.
No obvious cetuximab-related side effects were recorded
in this study. However, despite a favorable result in these
phase II trials, the results of a randomized phase III trial
comparing cetuximab in combination with capecitabine
and cisplatin with chemotherapy alone (EXPAND) were
negative. In this study, 904 patients were randomly
assigned (1:1) to receive first-line chemotherapy (capecita-
bine and cisplatin) with or without cetuximab (400 mg/m2
on day 1, subsequently 250 mg/m2). The primary endpoint
was PFS. The median PFS and OS were 4.4 and
9.4 months, respectively, in patients assigned to cetuximab
plus chemotherapy compared with 5.6 and 10.7 months
in patients receiving chemotherapy, respectively (PFS,
p = 0.3158; OS, p = 0.9547) [36]. Addition of cetuximab
provided no additional benefit to chemotherapy alone in
the first-line treatment of advanced gastric cancer.
Panitumumab
Panitumumab is a fully human, immunoglobulin G2 mo-
noclonal antibody directed against the EGFR. In meta-
static colorectal cancer, panitumumab has monotherapy
activity in patients with chemotherapy refractory diseases
and, when added to chemotherapy, can improve PFS in
Kirsten-ras (KRAS) oncogene wide type patients in the
first line and second line settings.
The REAL-3 trial was designed to compare combin-
ation chemotherapy (epirubicin/oxaliplatin/capecitabine,
EOX regimen) with or without panitumumab in 553
patients with advanced esophagogastric adenocarcinoma
at 63 centers. Median OS in 275 patients allocated to
EOX was 11.3 months (95% CI 9.6-13.0) compared
with 8.8 months (95% CI 7.7-9.8) in 278 patients allo-
cated panitumumab group (HR 1.37, 95% CI 1.07-1.76;
P = 0.013). Panitumumab group was associated with
increased incidence of grade 3–4 diarrhoea, rash, muco-
sitis and hypomagnesaemia but reduced incidence of
haematological toxicity [37].
Based on the results above, no more clinical trials of
anti-EGFR monoclonal antibody in gastric cancer will becarried out. Moreover, neither erlotinib nor gefitinib
showed activity in anti-gastric cancer in phase III studies.
VEGF-signaling pathway
Tumor angiogenesis and metastasis are strongly linked
with angiogenesis in most solid tumors. VEGF is a key
mediator of physiologic and pathologic angiogenesis [38].
Anti-VEGF monoclonal antibody
Preclinical studies showed that bevacizumab (Avastin,
Genentech/Roche, San Francisco, CA/Basel, Switzerland),
a monoclonal antibody targeting VEGF-A, resulted in
tumor growth inhibition when given as monotherapy or in
combination with cytotoxic agents [39]. In patients with
gastric cancer, VEGF expression has been linked to tumor
aggressiveness and poor prognosis [14,40-42]. Several
phase II trials combining bevacizumab with different
chemotherapeutic compounds were conducted on treat-
ment-naïve or pretreated patients with AGC or GEJ
cancers [43-45]. AVAGAST was a prospective, random-
assignment, double-blind, placebo-controlled phase III
clinical trial comparing capecitabine/cisplatin with or
without bevacizumab as first-line therapy in 774 patients
with AGC [46]. The primary endpoint was OS. Although
AVAGAST did not reach its primary endpoint (OS: 12.1
vs. 10.1 months for the bevacizumab and placebo groups
(HR, 0.87; P = 0.1002)), both median PFS (6.7 v 5.3
months; HR, 0.80; 95% CI, 0.68 to 0.93; P = 0.0037) and
RR (46.0% v 37.4%; P = 0.0315) were significantly im-
proved with bevacizumab versus placebo. The incidence
of grades 3 to 4 AEs potentially related to bevacizumab
was similar in both arms.
Anti-VEGFR monoclonal antibody
Ramucirumab (IMC-1121B; Im Clone Systems, New York,
NY) is a fully human immunoglobulin G1 monoclonal
antibody that binds with high affinity to the extracellular
VEGF-binding domain of VEGFR-2. Phase I clinical trials
demonstrated its objective antitumor activity and antian-
giogenic effects over a wide range of dose levels, suggest-
ing that ramucirumab may have a favorable therapeutic
index in treating malignancies amenable to VEGFR-2 in-
hibition [47].
REGARD study [48] is a phase III, randomized,
double-blinded trial of ramucirumab in the treatment of
AGC or GEJ adenocarcinoma in second line setting.
Patients were randomized 2:1 to receive ramucirumab
(8 mg/kg IV) plus BSC or placebo plus BSC every 2
weeks until PD, unacceptable toxicity, or death. The
primary endpoint was OS. The HR for OS was 0.776
(95% CI, 0.603-0.998; P = 0.0473). Median OS was 5.2
months for ramucirumab group and 3.8 months for
placebo group. The HR for PFS was 0.483 (95% CI,
0.376-0.620; p < 0.0001). Median PFS was 2.1 and 1.3
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and 2.6% for ramucirumab and placebo groups respect-
ively. The most frequent grade ≥ 3 AEs were: hyperten-
sion, anemia, abdominal pain, ascites and fatigue.
Ramucirumab conferred a statistically significant benefit
in OS and PFS compared to placebo in AGC in the sec-
ond line setting with an acceptable safety profile. The
phase III trial RAINBOW is a randomized multicenter
double-blind, placebo controlled trial evaluating the
safety and efficacy of paclitaxel plus ramucirumab drug
product compared to paclitaxel plus placebo. This study
is still on-going. Another randomized phase II clinical
trial of mFOLFOX6 plus ramucirumab vs. placebo for
AGC is also ongoing (Table 1).
VEGFR TKI
Apatinib (YN968D1) is a small-molecular TKI agent tar-
geting at VEGFR [49]. In a randomized, double-blind,
multicenter, phase II, three-arm, placebo-control study
of apatinib in patients with metastatic gastric carcinoma,
patients were randomized to receive placebo or apatinib
(placebo vs. apatinib at 850 mg once a day vs. 425 mg
twice a day) [50]. The primary endpoint was PFS. The re-
spective survival rates were as follows: median PFS, 1.4
months vs. 3.4 months vs. 3.4 months; median OS, 2.5
months vs. 4.8 months vs. 4.3 months. Common AEs in-
cluded hypertension and hand-foot syndrome. Based on
this result, a randomized, double blinded, placebo con-
trolled multicenter phase III study in a third-line setting in
AGC is currently being conducted in China. Patients are
scheduled to receive apatinib 850 mg qd or placebo until
PD or intolerable toxicity or patients’ withdrawal of con-
sent. The primary endpoint is PFS (NCT01512745).
VEGF trap
Aflibercept (VEGF Trap, Sanofi, Paris France; and
Regeneron, Tarrytown, NY, USA) is a recombinant fu-
sion protein consisting of extracellular domains of the
human VEGFR fused to the Fc portion of human im-
munoglobulin G1 [51-53]. Its biological affinity for
VEGF is reported to be significantly higher than that of
bevacizumab [54]; however, there are no preclinical data
to suggest its increased efficacy in AGC.
Aflibercept has recently been approved by the Food
and Drug Administration for patients with treatment-
resistant colorectal cancer. A phase II clinical trial to test
the safety and effectiveness of aflibercept in combination
with mFOLFOX6 compared to mFOLFOX6 alone in pa-
tients with AGC is ongoing.
Other targeted agents
MET inhibitor
c-Met is a proto-oncogene that encodes a protein known
as hepatocyte growth factor receptor (HGFR) [55,56]. Itstimulates cell scattering, invasion, protection from
apoptosis and angiogenesis [57]. Upon HGF stimulation,
MET induces MET kinase catalytic activity which trig-
gers transphosphorylation of the tyrosine (Tyr) 1234 and
Tyr 1235, thus initiating a whole spectrum of biological
activities driven by MET. A high level of c-Met expres-
sion has been correlated with poor survival in patients
with gastric cancer [58].
c-Met inhibitors include monoclonal antibodies and
small molecules that inhibit the enzymatic activity of the
c-Met TK. There are basically two classes of c-Met in-
hibitors, ATP competitive and ATP non-competitive
inhibitor. ATP competitive inhibitors are further divided
into two classes; class I (SU-11274-like) and class II
(AM7-like) on the basis of different types of binding and
a third group of noncompetitive ATP inhibitor that
binds in a different way to the other two [59,60].
Elevated expressions of c-MET and its ligand, HGF,
have been frequently found in gastric cancer, and are as-
sociated with a more aggressive disease [61,62]. Tivanti-
nib is a selective, non-ATP competitive, small-molecule
inhibitor of c-MET and is under development in several
cancers. In a single-arm phase II study, the efficacy of
tivantinib monotherapy in Asian patients with previously
treated AGC was evaluated [63]. Tivantinib was daily ad-
ministered 360 mg bid orally. The primary endpoint was
DCR. No objective response was observed, and DCR
was 36.7% (11/30 patients). Median PFS was 43 (95% CI:
29.0-92.0) days. There is no treatment-related death and
novel safety concern. Tivantinib as a monotherapy
showed a modest efficacy in previously treated AGC,
and further trial testing in combination would be war-
ranted in AGC.
Onartuzumab is a humanized mAb directed against
HGFR. A randomized, phase III, multicenter, double-
blind, placebo-controlled study evaluating the efficacy
and safety of onartuzumab in combination with mFOL-
FOX6 in patients with metastatic Her2-negative, c-Met-
positive gastroesophageal cancer is now ongoing.
m-TOR inhibitor
mTOR is a key protein kinase that regulates cell growth
and proliferation, cellular metabolism and angiogenesis
[64]. Mutations in these components result in inappro-
priate mTOR activation [64]. The mTOR pathway has
been shown to be frequently dysregulated in a variety of
human cancers, including gastric cancer [65]. Overex-
pression of the mTOR downstream effectors eIF4E and
4E binding protein 1 (4E-BP1) was shown in GI cancer
cells [64]. Everolimus (RAD001) is an oral inhibitor of
m-TOR, which is downstream of the Akt pathway.
Everolimus reduced 4E-BP1 phosphorylation and attenu-
ated production of the proangiogenic factors hypoxia-
inducible factor and VEGF in these gastric cancer cell
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ity in gastric cancer in preclinical studies [64-66] and a
phase I study involving patients with AGC [67]. The re-
sults of a phase IIstudy of everolimus in 53 patients with
previously treated AGC showed a disease control rate of
56.0% and median PFS of 2.7 months. At a median
follow-up duration of 9.6 months, the median OS was
10.1 months and good tolerability was observed [68].
Based on this promising result, a prospective phase III
trial of everolimus in previously treated patients with
advanced gastric cancer: GRANITE-1 was conducted
[69]. A total of 656 patients from 23 countries were
enrolled; 439 were randomized to everolimus, 217 to
placebo. Median OS was 5.39 months with everolimus
vs 4.34 months with placebo (HR, 0.90; 95% CI,
0.75-1.08; P = 0.1244). Median PFS was 1.68 vs 1.41
months (HR, 0.66; 95% CI, 0.56-0.78; p < 0.0001). The
most common grade 3/4 adverse events were anemia,
decreased appetite and fatigue. Everolimus monotherapy
did not significantly improve OS in patients with
AGC previously treated with 1 or 2 lines of systemic
chemotherapy.Future perspectives
Emerging data from the development of targeted therapy
have provided novel strategies that are expected to
translate into survival benefits for AGC patients. The re-
sults of the ToGA study recently demonstrated that the
addition of trastuzumab to chemotherapy can bring sur-
vival benefit to HER2-positive AGC patients. However,
this benefit is limited to only 20% of AGC patients
(HER2-positive). Therefore, there remains a critical need
for both the development of more effective agents and
the identification of predictive molecular markers to se-
lect those patients who might benefit most from specific
targeted therapies. Till now both cetuximab and bevaci-
zumab have failed in phase III trail for AGC. The results
of pertuzumab and T-DM1 are worth waiting for. The
other promising targeted agents include: ramucirumab,
aflibercept and apatinib as well as c-MET inhibitors.Abbreviations
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